Summit Q1 net loss $189.4M, cash $598.7M; ivonescimab OS data at ASCO plenary

Summit Therapeutics Inc.

2026-Q1 EPS reported -$0.24

GAAP net loss $189.4M ($0.24/sh) vs $62.9M ($0.09/sh) YoY; non-GAAP net loss $116.6M ($0.15/sh).
Cash and short-term investments $598.7M, down $114.7M from Dec 2025; cash burn funds ivonescimab trials.
HARMONi-6 (squamous NSCLC in China) OS data to be presented at ASCO 2026 plenary as late-breaking abstract.
HARMONi-3 squamous final PFS expected H2 2026; interim PFS cleared by iDMC, study continues blinded.
BLA for ivonescimab in EGFR-mutated NSCLC accepted; PDUFA date Nov 14, 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Summit Therapeutics Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On April 30, 2026, Summit Therapeutics Inc. (the “Company”) issued a press release announcing its financial results and operational progress for the first quarter ended March 31, 2026.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Summit Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001599298-26-000037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.